Statements (815)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
2
|
| gptkbp:bfsParent |
gptkb:physicist
|
| gptkbp:acquisition |
gptkb:Ethris_Gmb_H
gptkb:Aurelia_Bioscience gptkb:Alaunos_Therapeutics by Boehringer Ingelheim Ribologicals |
| gptkbp:addressed |
unmet medical needs
vaccine hesitancy |
| gptkbp:aims_to |
gptkb:healthcare_organization
immune response patient outcomes scientific knowledge improve patient outcomes improve cancer treatment treat cancer unmet medical needs vaccine development global health challenges immune system response reduce cancer mortality global vaccination efforts transform cancer treatment vaccine accessibility improve cancer treatment outcomes vaccine delivery systems develop innovative therapies transform medicine affordable vaccines address unmet medical needs improve vaccine efficacy cancer treatment outcomes enhance immune response personalized cancer vaccines improve cancer immunotherapy m RNA technology for various diseases reduce side effects of cancer treatment therapies for rare diseases broad-spectrum vaccines its vaccine portfolio patient outcomes in cancer the immune system's response |
| gptkbp:approves |
various clinical trials
clinical trials in multiple countries |
| gptkbp:awards |
gptkb:Frost_&_Sullivan_Award
gptkb:European_Innovation_Award gptkb:German_Innovation_Award various industry awards Red Herring Top 100 Europe |
| gptkbp:business_model |
collaborative development
biopharmaceutical development contract research |
| gptkbp:caliber |
proven efficacy
|
| gptkbp:ceo |
gptkb:Franz-Werner_Haas
|
| gptkbp:clinical_trial |
gptkb:healthcare_organization
gptkb:television_series gptkb:government_agency gptkb:Europe gptkb:Asia gptkb:United_States gptkb:drug Phase 1 multiple countries rare diseases Phase 2 Phase 3 chronic diseases biopharmaceuticals infectious diseases COVID-19 vaccine trials cancer immunotherapy various cancers cancer vaccine trials C V8102 Phase 1 C V8102 Phase 2 C Vn Co V Phase 1/2 C Vn Co V Phase 2b/3 Phase 1/2 trials for C Vn Co V Phase 3 trials for C Vn Co V breast cancer vaccine colorectal cancer vaccine head and neck cancer vaccine lung cancer vaccine melanoma vaccine ovarian cancer vaccine pancreatic cancer vaccine prostate cancer vaccine |
| gptkbp:collaborated_with |
gptkb:GSK
gptkb:Boehringer_Ingelheim government agencies non-profit organizations academic institutions healthcare providers international organizations pharmaceutical companies regulatory bodies research institutions regulatory agencies international research organizations biopharmaceutical companies biotech companies global health initiatives international health organizations biotech firms biomedical researchers leading scientists clinical research organizations vaccine efficacy studies government agencies for vaccine development |
| gptkbp:collaborates_with |
gptkb:temple
academic institutions various pharmaceutical companies various research institutions |
| gptkbp:collaborations |
gptkb:Charité_–_Universitätsmedizin_Berlin
gptkb:temple gptkb:University_of_Tübingen gptkb:Max_Planck_Institute gptkb:legislation gptkb:Sanofi gptkb:Harvard_University gptkb:University_of_Pennsylvania gptkb:Pfizer gptkb:Moderna gptkb:Coalition_for_Epidemic_Preparedness_Innovations_(CEPI) gptkb:U._S._Department_of_Defense academic institutions Lilly with academic institutions with pharmaceutical companies with the European Union with the Coalition for Epidemic Preparedness Innovations (CEPI) Merck K Ga A with the Bill & Melinda Gates Foundation with the German government |
| gptkbp:committee |
composed of experts
|
| gptkbp:conference |
participates in biotechnology conferences
|
| gptkbp:constructed_in |
strategic alliances
a global presence in biotechnology. a pipeline of vaccine candidates |
| gptkbp:cultural_representation |
scientists and researchers
experts in various fields vaccine candidates therapeutic candidates product pipeline biopharmaceutical products m RNA-based products |
| gptkbp:dedicated_to |
scientific excellence
patient safety scientific innovation sustainable health solutions advancing medical science improving healthcare outcomes |
| gptkbp:depicted_in |
gptkb:NASDAQ
|
| gptkbp:developed_by |
COVID-19 vaccine candidate
C V8102 Cure Vac C Vn Co V |
| gptkbp:developer |
academic institutions
regulatory agencies cancer vaccines biomarker identification combination therapies multiple cancer types cancer immunotherapy clinical research organizations vaccine candidates therapeutic vaccines therapeutics for autoimmune diseases therapeutics for cancer therapeutics for infectious diseases therapeutics for cardiovascular diseases therapeutics for metabolic disorders therapeutics for rare diseases therapeutics for chronic diseases novel therapeutic strategies therapeutics for neurological disorders personalized cancer vaccines therapeutic applications of m RNA m RNA-based therapeutics cancer immunotherapy solutions m RNA-based cancer therapies m RNA-based therapies m RNA-based treatments m RNA-based vaccines for infectious diseases therapeutic m RNA vaccines therapeutic solutions for cancer cancer immunotherapies next-generation vaccines m RNA vaccines for various diseases m RNA-based therapies for cancer prophylactic m RNA vaccines therapeutic vaccines for other cancers vaccine stability improvements m RNA-based cancer vaccines m RNA-based therapies for infectious diseases m RNA-based therapies for various conditions therapeutic m RNA products therapeutic m RNA vaccines for various cancers therapeutic vaccines for various cancers novel cancer vaccines |
| gptkbp:develops |
vaccines
therapeutics therapeutics for COVID-19 therapeutics for infectious diseases m RNA vaccines m RNA therapeutics m RNA cancer vaccines m RNA-based vaccines COVID-19 vaccine candidates |
| gptkbp:employees |
over 500
over 200 over 400 over 300 growing rapidly |
| gptkbp:enhances |
immune response
regulatory approvals global health equity vaccine innovation global health solutions new treatment modalities a tuberculosis-free world a vaccine for HIV improving cancer immunotherapy outcomes |
| gptkbp:established |
international collaborations
strategic alliances clinical trial sites manufacturing capabilities global partnerships for research |
| gptkbp:expansion_plans |
new vaccine candidates
|
| gptkbp:explores |
combination therapies
new delivery methods vaccine delivery methods new therapeutic modalities combination therapies for cancer new therapeutic areas new vaccine platforms novel delivery systems therapeutic applications of m RNA combination immunotherapies new delivery methods for vaccines therapeutic vaccines. new applications for m RNA technology new delivery methods for m RNA |
| gptkbp:flows_into |
therapeutics
therapeutics and vaccines therapeutic candidates therapeutic vaccines |
| gptkbp:focus |
m RNA technology
|
| gptkbp:focus_area |
m RNA technology
|
| gptkbp:focuses_on |
gptkb:healthcare_organization
gptkb:vaccine research and development patient safety regulatory compliance sustainable practices oncology personalized medicine rare diseases patient-centered approaches clinical research targeted therapies immuno-oncology regenerative medicine safety and efficacy developing effective treatments infectious diseases clinical trial design vaccine development scientific innovation global health challenges cancer prevention long-term health outcomes clinical applications clinical efficacy cancer immunotherapy innovative treatment options sustainable healthcare solutions global health equity patient-centered solutions patient safety. patient-centric solutions scalable manufacturing solutions vaccine innovation vaccine accessibility clinical development therapeutic vaccines patient education. therapeutics for cancer innovative drug delivery systems patient-centric approaches safety and efficacy of vaccines innovative drug delivery methods m RNA technology m RNA technology advancements m RNA vaccine development vaccine safety and efficacy m RNA-based therapies patient-centric therapies next-generation vaccines biomanufacturing capabilities clinical trial advancements global access to therapies scalable vaccine production developing next-generation vaccines developing novel therapies infectious diseases and cancer patient-centered therapies vaccine development for infectious diseases |
| gptkbp:founded |
gptkb:Ingmar_Hoerr
gptkb:2000 gptkb:Hermann_Wagner therapeutic vaccines Daniel Menning |
| gptkbp:founder |
gptkb:Ingmar_Hoerr
m RNA technology m RNA therapeutics the use of m RNA for therapeutic purposes |
| gptkbp:future_plans |
global market expansion
expand product pipeline increase partnerships enhance technology platform |
| gptkbp:global_presence |
clinical trials
biotechnology sector |
| gptkbp:grants |
government agencies
research foundations |
| gptkbp:has_achievements |
regulatory approvals
clinical milestones regulatory approvals for trials |
| gptkbp:has_awards |
innovation in biotechnology
|
| gptkbp:has_expansion |
global presence
global footprint new therapeutic areas clinical trial capabilities |
| gptkbp:has_experience_in |
regulatory challenges
|
| gptkbp:has_goal |
reduce cancer mortality
improve survival rates enhance vaccine efficacy develop next-generation vaccines |
| gptkbp:has_mission |
improve global health
transform medicine transform medicine through m RNA technology transform medicine with m RNA technology transform medicine with m RNA |
| gptkbp:has_part |
gptkb:Cure_Vac's_pipeline
gptkb:Cure_Vac_AG clinical data clinical trials partnerships clinical research manufacturing facilities business development team partnerships with universities research and development team quality assurance team research collaborations regulatory affairs team vaccine candidates C Vn Co V C V8102 C V9202 m RNA platform patents on m RNA technology |
| gptkbp:has_team |
scientists and researchers
|
| gptkbp:headquartered_in |
gptkb:government_agency
gptkb:Tübingen,_Germany |
| gptkbp:headquarters |
gptkb:Tübingen,_Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cure Vac
|
| gptkbp:influenced_by |
new vaccine platforms
m RNA-based therapies new vaccine modalities |
| gptkbp:infrastructure |
m RNA-based therapies
|
| gptkbp:innovation |
vaccine technology
|
| gptkbp:invention |
m RNA vaccines
m RNA delivery systems m RNA technology m RNA therapeutics m RNA technology patents m RNA stabilization methods m RNA vaccine formulations therapeutic m RNA compositions |
| gptkbp:investment |
gptkb:Bill_&_Melinda_Gates_Foundation
gptkb:Boehringer_Ingelheim gptkb:European_Investment_Bank gptkb:Deutsche_Bank $1 billion research and development oncology rare diseases autoimmune diseases venture capital firms infectious diseases m RNA technology from public markets from venture capital firms |
| gptkbp:ipo |
gptkb:2020
|
| gptkbp:is_aimed_at |
reduce healthcare costs
improve patient outcomes reduce disease burden reduce cancer mortality accelerate drug development improve global health outcomes reduce treatment costs treatment costs transform cancer treatment improve treatment adherence improve vaccine accessibility enhance immune response reduce treatment side effects enhance vaccine efficacy improve global vaccination rates eliminate HIV transmission. reduce the burden of HIV reduce vaccine development timelines reduce the burden of cancer globally |
| gptkbp:is_committed_to |
community engagement
scientific excellence research and development patient safety sustainability sustainable practices ethical research practices environmental sustainability ethical practices scientific integrity safety and efficacy transparency in research innovation in healthcare improving patient outcomes research and innovation in healthcare cancer treatment options sustainable healthcare solutions patient-centered solutions patient-centric solutions innovation in medicine improving global health sustainability in biotech patient-centric approaches diversity in clinical trials patient-centric research advancing m RNA technology make healthcare more effective. meet global health challenges scientific knowledge in medicine |
| gptkbp:is_engaged_in |
gptkb:scientific_collaborations
community outreach programs public health initiatives clinical research biomedical research global health initiatives public health research therapeutic development vaccine development vaccine research public health discussions patient advocacy efforts regulatory affairs patient advocacy initiatives biopharmaceutical development vaccine research and development vaccine safety studies partnerships for research clinical research partnerships therapeutic innovation patient recruitment for trials patient-centric research clinical trials for cancer vaccines clinical trials for lung cancer scientific education efforts |
| gptkbp:is_enhanced_by |
gptkb:scientific_collaborations
patient outcomes vaccine efficacy clinical trial efficiency therapeutic efficacy biomanufacturing patient education initiatives patient access to therapies public trust in vaccines patient recruitment strategies vaccine delivery methods vaccine development processes clinical trial designs m RNA technology applications clinical trial accessibility patient outcomes through research safety profiles of vaccines therapeutic efficacy through research. vaccine stability the delivery mechanisms for m RNA vaccines the efficacy of cancer treatments the safety profile of vaccines |
| gptkbp:is_integrated_with |
multiple cancer vaccines
multiple m RNA-based therapies |
| gptkbp:is_involved_in |
COVID-19 vaccine development
clinical trials community outreach programs personalized medicine public health initiatives community health initiatives clinical research biomedical research public health campaigns global health initiatives clinical trial design regulatory submissions vaccine distribution vaccine development global health challenges healthcare innovation vaccine research cancer immunotherapy clinical research trials community engagement efforts clinical trial design. biopharmaceutical development vaccine research and development vaccine distribution efforts biopharmaceutical research vaccine innovation clinical research collaborations healthcare innovation. vaccine safety studies vaccine distribution strategies vaccine efficacy studies vaccine education initiatives clinical trials for cancer vaccine accessibility initiatives clinical outcome assessments the development of novel vaccine strategies |
| gptkbp:is_known_for |
cutting-edge technology
scientific advancements scientific publications cancer vaccines high-quality research cutting-edge research innovative therapies innovative vaccine solutions its innovative approach the fight against cancer innovative vaccine development m RNA technology m RNA technology advancements innovative m RNA technology its innovative m RNA technology its m RNA platform its m RNA technology its m RNA technology platform innovative vaccine technology its COVID-19 vaccine development its innovative approach to vaccines its proprietary m RNA technology pioneering m RNA technology vaccine science |
| gptkbp:is_often_associated_with |
global partnerships
|
| gptkbp:is_part_of |
gptkb:the_European_Innovation_Council
biotech industry the fight against cancer biopharmaceutical industry biotech ecosystem global vaccine efforts the biotechnology industry the biotechnology sector European vaccine development efforts the m RNA vaccine ecosystem the m RNA vaccine revolution the m RNA vaccine market |
| gptkbp:is_recognized_by |
industry experts
industry awards a leader in m RNA technology |
| gptkbp:is_recognized_for |
gptkb:scientific_collaborations
scientific excellence scientific advancements scientific achievements scientific contributions scientific publications clinical trial results vaccine development scientific innovation innovative therapies collaborative approach its contributions to science its contributions to science. its innovative approaches innovation in biotechnology its scientific contributions its contributions to public health its research in immunology its ethical practices its scientific expertise its research and development efforts its innovative therapies its contributions to immunotherapy its research in m RNA its role in pandemic response pioneering m RNA therapeutics its contribution to m RNA technology its contributions to biotechnology its innovative approach to m RNA technology its innovative approach to vaccines its innovative vaccine platforms pioneering m RNA technology its contributions to m RNA technology |
| gptkbp:is_sought_after_by |
regulatory approval
enhance treatment efficacy expand its pipeline expand its product pipeline to expand its product portfolio |
| gptkbp:is_supported_by |
gptkb:Research_Institute
government grants |
| gptkbp:is_vulnerable_to |
C Vn Co V
|
| gptkbp:key_people |
biotechnology sector
the m RNA vaccine landscape the biotechnology sector. |
| gptkbp:language_of_instruction |
multiple candidates
therapeutic vaccines prophylactic vaccines |
| gptkbp:leadership |
gptkb:Franz-Werner_Haas
m RNA technology m RNA therapeutics m RNA vaccine technology m RNA vaccine development m RNA technology development the field of m RNA therapeutics |
| gptkbp:led_to |
gptkb:Franz-Werner_Haas
gptkb:Franz-Ulrich_Hartl scientific experts a team of scientists and researchers a team of scientists a team of scientists and entrepreneurs CEO Franz-Werner Haas |
| gptkbp:market |
global
vaccines biopharmaceuticals therapeutics diagnostics |
| gptkbp:marketing_strategy |
partnerships
licensing agreements collaborative research global vaccine distribution enhance vaccine efficacy develop next-generation vaccines |
| gptkbp:members |
biotech associations
biotechnology associations |
| gptkbp:mission |
develop m RNA-based medicines
|
| gptkbp:notable_products |
C Vn Co V
C V8102 Cure Vac's m RNA cancer vaccines |
| gptkbp:open_to_public |
gptkb:NASDAQ
gptkb:Euronext_Amsterdam |
| gptkbp:origin |
cancer immunotherapy
scientific research. m RNA technology applications cancer vaccine development m RNA vaccine technology. m RNA technology for vaccines the field of immunotherapy the field of precision medicine |
| gptkbp:participated_in |
international collaborations
global health initiatives international conferences international research projects vaccine consortia |
| gptkbp:partnership |
gptkb:Eli_Lilly
gptkb:GSK gptkb:temple gptkb:Takeda_Pharmaceutical_Company gptkb:Sanofi gptkb:Bayer_AG gptkb:Boehringer_Ingelheim gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Moderna gptkb:Roche gptkb:Amgen gptkb:Sana_Biotechnology gptkb:Astellas_Pharma gptkb:Cure_Vac_AG gptkb:Novartis pharmaceutical companies Merck K Ga A |
| gptkbp:partnerships |
academic institutions
pharmaceutical companies various pharmaceutical companies |
| gptkbp:performed_by |
clinical trials
clinical studies |
| gptkbp:platform |
m RNA technology platform
m RNA-based therapeutics m RNA-based diagnostics m RNA-based vaccines |
| gptkbp:production_company |
oncology portfolio
|
| gptkbp:products |
C Vn Co V
C V8102 C Vn Co V-2 |
| gptkbp:promotes |
vaccine literacy
|
| gptkbp:publishes |
peer-reviewed journals
numerous scientific papers vaccine efficacy COVID-19 vaccines various cancers various infectious diseases m RNA vaccines m RNA delivery systems m RNA technology m RNA stability immune response to m RNA vaccines m RNA vaccine efficacy |
| gptkbp:received |
various awards
regulatory approvals |
| gptkbp:receives_funding_from |
gptkb:Company
gptkb:NASDAQ gptkb:European_Investment_Bank gptkb:Series_A gptkb:Series_B gptkb:public_funding cutting-edge technology data analytics government grants Series D Series C $1.3 billion IPO various investors advanced technology platforms public and private investors data analytics in research |
| gptkbp:regulatory_compliance |
gptkb:European_Medicines_Agency_(EMA)
gptkb:FDA gptkb:European_Medicines_Agency gptkb:U._S._Food_and_Drug_Administration_(FDA) clinical trials some of its products some of its vaccine candidates |
| gptkbp:research |
gptkb:Dr._Franz-Ulrich_Hartl
autoimmune diseases infectious diseases cancer vaccines various types of cancer therapeutic vaccines prophylactic vaccines other diseases other types of cancer vaccines |
| gptkbp:research_areas |
gptkb:Tübingen
gptkb:government_agency gptkb:Boston rare diseases infectious diseases cancer immunotherapy |
| gptkbp:research_focus |
gptkb:vaccine
oncology personalized medicine rare diseases autoimmune diseases vaccines therapeutics infectious diseases cancer immunotherapy |
| gptkbp:shoots |
infectious diseases
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
gptkb:theorem gptkb:battle on NASDAQ the NASDAQ |
| gptkbp:strategic_importance |
market expansion
future growth |
| gptkbp:symbol |
CVAC
|
| gptkbp:technology |
gptkb:physicist
clinical data therapeutics preclinical studies messenger RNA vaccine development therapeutic proteins RNA therapeutics diagnostics delivery systems immune response enhancement RNA-based vaccines m RNA m RNA vaccines m RNA therapeutics m RNA-based therapeutics m RNA cancer vaccines m RNA platform stability of m RNA |
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:uses |
messenger RNA
RNA-based therapies m RNA technology |
| gptkbp:utilizes |
gptkb:advanced_technology
gptkb:Company cutting-edge technology state-of-the-art technology advanced manufacturing techniques bioinformatics tools genetic engineering state-of-the-art facilities advanced manufacturing processes lipid nanoparticles RNA-based therapies advanced delivery systems novel delivery systems cutting-edge research methodologies data analytics for research lipid nanoparticles for delivery proprietary m RNA technology bioinformatics in research data analytics in research |
| gptkbp:vision |
the future of healthcare
global health improvement transform healthcare with m RNA technology revolutionize healthcare revolutionize vaccine development transform medicine through m RNA technology revolutionize vaccine technology |
| gptkbp:website |
www.curevac.com
|
| gptkbp:year_created |
gptkb:2000
|